Singapore is firmly establishing itself as Southeast Asia’s strategic hub for global biotech innovation, says a new report titled “Empowering Biotech Innovation in Asia-Pacific” by Bain & Company.
It is a testament to decades of visionary planning and sustained investment. With its unwavering commitment to innovation, political neutrality, robust intellectual property (IP) protections, and world-class infrastructure, the city-state offers an unparalleled environment for biotech startups and multinational corporations alike.
A foundation built on vision and investment
Singapore’s journey in biomedical sciences began nearly three decades ago, underpinned by a holistic strategy encompassing infrastructure, talent, and private sector development.
Also Read: Asia Pacific redefines biotech: Global pharma’s strategic shift from West to East
Key milestones include the National Science Scholarship programme, the establishment of BioOne Capital by the EDB to invest in 50 local and overseas companies, and the creation of Biopolis, a purpose-built hub dedicated to biomedical sciences.
Today, Singapore’s ongoing Research, Innovation, and Enterprise (RIE) plan allocates substantial public funds, with S$28 billion (approximately US$20.72 billion) earmarked for science and technology development under RIE2025 (2020–25), and a similar commitment planned for RIE2030.
Strategic pillars: Talent, regulation, and infrastructure
Singapore’s appeal as a trusted hub for biotech expansion rests on several strategic pillars:
- Talent attraction: The government has launched individual talent visa programmes such as ONE Pass and Tech.Pass to attract top talent, including founders and technical experts, from around the world. Initiatives like SGInnovate’s Helix Immersion Programme further integrate research talent into commercial ventures.
Innovation-friendly policy: Singapore offers a strong IP regime and biotech-friendly tax structures, alongside the ability to conduct first-in-world regulatory evaluations and work-sharing arrangements with international regulatory agencies like the FDA and EMA.
World-class infrastructure: The Biopolis hub co-locates public research institutes, startups, and multinational corporations, facilitating seamless research translation. The city-state’s expanding capacity in advanced modalities like CGT is supported by facilities such as ACTRIS’s 2,000-square-metre CGT R&D and manufacturing site, alongside incubators like NSG BioLabs and dedicated land plots in Tuas Biomedical Park.
Success stories and global partnerships
Singapore’s ecosystem has nurtured and attracted global leaders, validating its position as a burgeoning biotech powerhouse:
Also Read: Asia-Pacific governments step in as private biotech investors pull back
- Hummingbird Bioscience, a Singapore-based clinical-stage biotech focused on precision biologics, has raised over US$150 million and recently spun out its ADC platform into Callio Therapeutics, which launched with US$187 million in Series A funding.
- Mirxes, an RNA technology company pioneering early disease detection, achieved unicorn status on the Hong Kong Stock Exchange in May 2025 with US$180 million in venture funding, becoming the first Southeast Asian biotech to do so. Its flagship cancer screening product, GASTROClear, is set to ramp up operations across Asia-Pacific.
- Chugai Pharmabody Research (CPR), a subsidiary of Japan’s Chugai Pharmaceutical, invested over US$300 million in Singapore, leading to the creation of crovalimab, the first globally approved drug originating from Singapore. CPR’s collaboration with A*STAR and the National University of Singapore (NUS) on an anti-dengue antibody has further advanced with a new development partnership with GSK.
- Major global players are deepening their commitment, with WuXi Biologics investing US$1.4 billion into local R&D and manufacturing infrastructure, and AstraZeneca establishing its first-ever US$1.5 billion end-to-end ADC manufacturing facility in Singapore. Flagship Pioneering, the venture creation firm behind Moderna, also launched its regional hub in Singapore, committing up to S$100 million (approximately US$74 million*) with A*STAR to advance biotech and healthtech innovation.
Also Read: AI, advanced therapeutics, and the geopolitical balancing act in biotech
By consistently investing in foundational scientific capabilities, fostering a stable environment for startups, and attracting top-tier talent, Singapore is not just a regional R&D base but a gateway to broader international markets, solidifying its role as Southeast Asia’s anchoring hub for global biotech innovation.
The post Why global pharma giants are doubling down on Singapore appeared first on e27.